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Letter to the Editor
Reflections and recommendations on the COVID-19 pandemic: Should hormone therapy be
discontinued?
Since the COVID-19 pandemic outbreak, the extent of serious
complications and high rate of mortality has concerned all the health
authorities worldwide. Death by COVID-19 is mainly due to acute re-
spiratory distress syndrome (ARDS), although heart and multiple organ
failure may contribute [1]. Underlying mechanisms are COVID-19-in-
duced endothelial alteration, cytokine storm, inflammation, exudation
in the lungs, and vessel occlusion.
1. Difference between sexes
Mortality by COVID-19 is higher in men than in women. Among the
advocated reasons are a different exposure to risk factors such as
smoking, reduced care of men about their health or different associa-
tion with other morbidities. Nevertheless, a different expression of
ACE2 may explain the different mortality between sexes. COVID-19
disease progression is reduced by ACE2 enzyme expression in en-
dothelial cells mainly at the lung and heart, where it exerts vasodi-
lating, anti-inflammatory and anticoagulant effects [2]. ACE2 is coded
by the X chromosome, of which men have only one, and ACE2 ex-
pression in endothelial cells is stimulated by estrogens [2]. The possi-
bility that this mechanisms accounts for the lower mortality of women
vs. men (Yi et al.) is sustained by the recent evidence that reduced
mortality (−72 %) of fertile women vs. men is lost, at least in part, in
the postmenopausal years (−49.6 %) [3].
2. Hormone therapy
These data lead to speculation that hormone therapy or even po-
tentiating estrogen stimulus by exogenous estrogens may antagonize
the deadly progression of the disease. On the other hand, exogenous
estrogens may increase coagulating factors and the risk of throm-
boembolic events with a potential consequent increase in mortality.
Hospitalized individuals with very severe COVID-19 disease have an
activated coagulation defined by high levels of D-dimers, products of
fibrin degradation, and when D-dimer levels are very high, antic-
oagulants like heparin may reduce mortality [4]. In order to decrease
the risk of thromboembolic events a recent publication has re-
commended that peri- and post-menopausal women immediately
withdraw from exogenous hormone administration after becoming in-
fected by COVID-19 [5]. This position stimulates some considerations.
1) Thrombophilic states are not among the comorbidities that ac-
celerate COVID-19 disease progression. To date, there is no report
documenting that the most thrombophilic state in woman life, i.e.
pregnancy, or even hormonal contraceptive use [6], is associated with a
worst prognosis of COVID-19 infection. 2) Locally formed thrombi,
consequent to massive endothelial disruption and local activation of the
extrinsic coagulation cascade, rather than cloth emboli, appear to oc-
clude lung vessels of COVID-19-infected individuals in the last stage of
disease [4]. Indeed, the evidence that many women with occluded lung
vessels lack peripheral vein thrombosis challenges the theory of a
massively increased thrombophilic condition [4]. Of the Virchow triad
explaining blood clot formation, i.e. increased coagulation, blood stasis
and altered endothelium, it is the third component that is highly pre-
valent in COVID-19 individuals, the contribution of increased coagu-
lation being unknown and probably negligible [4]. 3) The dose of he-
parin used in COVID-19-infected individuals (80−100mg) exceeds the
prophylactic dose for thrombophilic states. 4) A putative increased risk
of venous thrombosis due to increased synthesis of coagulation factors
is mainly limited to the first two years of oral estrogen administration,
and up to now no study has reported a thrombophilic effect of trans-
dermal estrogens [7]. 5) Perimenopausal women requiring hormonal
contraception are usually in their late forties and postmenopausal
women start their hormone therapy for symptoms before 60 years of
age. In these years, mortality from COVID-19 is below 1 % [3], and
there is no report that it is higher in women on hormones.
3. Conclusions
At first sight, indications for COVID-19-positive individuals to
withdraw from hormone therapy or oral contraceptives may seem a
wise recommendation, but it is not based on real data. It takes into
consideration only one side of the coin, the procoagulant activity of
exogenous oral estrogens. This effect for COVID-19 patients is likely the
least important. In these individuals, increased coagulation is con-
sequent to massive endothelial disruption and to the activation of the
extrinsic coagulation cascade, with no evidence that an increase in
coagulating factors plays any role [4]. By contrast, the advice to
withdraw from estrogens misses a consideration of the main effect of
estrogens, i.e. their ability to stimulate ACE2 enzyme expression, a
critical factor in reducing mortality from COVID-19 [2].
4. Recommendations
On these bases, we suggest that advice for COVID-19-infected
women should be:
a Hormone therapy or hormonal contraceptives [6] should be con-
tinued, unless the woman is severely ill, a condition in which hor-
monal balance is probably not so crucial. In the other conditions, the
possibility that hormone withdrawal may accelerate COVID-19
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progression cannot be excluded, and withdrawal should be avoided.
b In case of disease progression from a simple flu to more severe
symptoms, it seems wise to rely on expertise of specialists who will
consider the need of adding heparin, useful as anticoagulant, anti-
inflammatory and immune-modulator [4].
c Shifting from oral to transdermal estrogens (patch, gel, spray) may
be considered, but is not mandatory.
d In order to start or restart therapy, it is probably useful to use
transdermal instead of oral estrogens.
e In the case that hormone therapy is discontinued, it should be re-
membered that withdrawal bleedings may occur.
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